Log in

Relevant bibliographies by topics / Infusion / Journal articles

To see the other types of publications on this topic, follow the link: Infusion.

Journal articles on the topic 'Infusion'

Author: Grafiati

Published: 4 June 2021

Last updated: 25 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Infusion.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Buddington, Randal K., Karyl K. Buddington, and Scott C. Howard. "Multiple Asparaginase Infusions Cause Increasingly Severe Acute Hyperammonemia." Medical Sciences 10, no. 3 (2022): 43. http://dx.doi.org/10.3390/medsci10030043.

Full text

Abstract:

Adverse reactions during and shortly after infusing asparaginase for the treatment of acute lymphoblastic leukemia can increase in severity with later doses, limiting further use and increasing relapse risk. Although asparaginase is associated with hyperammonemia, the magnitude of the increase in serum ammonia immediately after the infusion and in response to multiple infusions has not been examined. The concurrence of hyperammonemia and infusion reactions was studied using weaned juvenile pigs that received 12 infusions of Erwinia asparaginase (Erwinase; 1250 U/kg) over 28 days, with two 5-da

APA, Harvard, Vancouver, ISO, and other styles

2

Goldfeld, Ester, Leigh Cantrell, and Marilyn Huang. "Paclitaxel hypersensitivity reaction (HSR) rate: Titrated versus non-titrated infusions among gynecologic oncology patients." Journal of Clinical Oncology 42, no. 16_suppl (2024): e23240-e23240. http://dx.doi.org/10.1200/jco.2024.42.16_suppl.e23240.

Full text

Abstract:

e23240 Background: Paclitaxel is a common chemotherapeutic agent used for treatment of various cancers, and is associated with hypersensitivity reactions (HSR). An HSR is mostly likely to occur during first or second infusions. Prior studies have suggested that performing Paclitaxel infusions without titration may be safe for the majority of patients, but increase in number of HSRs. At our institution, Paclitaxel infusions without titration was implemented around April 2023. Our aim was to evaluate the rate of HSR in Paclitaxel infusions without titration among gynecologic patients. Methods: T

APA, Harvard, Vancouver, ISO, and other styles

3

Jagt, J., S. Galestin, M. Benninga, N. de Boer, and T. de Meij. "P673 The safety of rapid versus standard infliximab infusions in children with inflammatory bowel disease: a multi-centre retrospective cohort study." Journal of Crohn's and Colitis 17, Supplement_1 (2023): i804—i805. http://dx.doi.org/10.1093/ecco-jcc/jjac190.0803.

Full text

Abstract:

Abstract Background Rapid infliximab (IFX) infusions have shown to be safe in adults with inflammatory bowel disease (IBD), but data on its safety in paediatric IBD is limited. This study aimed to assess the frequency and timing of infusion reactions (IR) in children with IBD who received rapid (1-h) vs. standard (2-h) IFX infusions. Methods This retrospective cohort study included IBD patients 4-18 years old, treated with IFX between January 2006 - November 2021 at two tertiary centres (AMC and VUmc) in Amsterdam, the Netherlands. The AMC protocol was adjusted from standard to rapid infusions

APA, Harvard, Vancouver, ISO, and other styles

4

Abushamma, Suha, Ted Walker, Kevin Garza, and Chien-Huan Chen. "ACCELERATED INFLIXIMAB INFUSION SAFETY AND TOLERABILITY IS NON-INFERIOR TO STANDARD INFUSION PROTOCOL IN INFLAMMATORY BOWEL DISEASE PATIENTS – A RANDOMIZED CONTROLLED STUDY." Inflammatory Bowel Diseases 29, Supplement_1 (2023): S8—S9. http://dx.doi.org/10.1093/ibd/izac247.018.

Full text

Abstract:

Abstract BACKGROUND & AIM Infliximab is typically given over a standard infusion time of 2 hours, leading to a significant burden in inflammatory bowel disease (IBD) patients. Several retrospective and prospective studies have assessed the safety of accelerated infliximab infusions, but not in a randomized controlled setting. We aimed to determine the safety and cost-effectiveness of an accelerated infliximab infusion of 1 hour, compared to the standard 2 hour infusion. METHODS This open label randomized trial was done at a tertiary IBD center in the United States. Patients with an establi

APA, Harvard, Vancouver, ISO, and other styles

5

Munsel, Erin J., Peter J. Bryan, Bryce A. Binstadt, et al. "Rapid Infliximab Infusion in the Pediatric Population." Journal of Pediatric Pharmacology and Therapeutics 25, no. 8 (2020): 705–8. http://dx.doi.org/10.5863/1551-6776-25.8.705.

Full text

Abstract:

OBJECTIVES To compare infusion reaction rates between rapid infliximab (REMICADE, Janssen Biotech Inc) infusions and previous standard 2- to 3-hour infusions; additionally, to assess patient satisfaction and reduction in chair time associated with rapid infliximab infusions. METHODS Pediatric rheumatology and gastroenterology patients receiving maintenance infliximab therapy using a standard 2- to 3-hour titrated infusion had the opportunity to enroll in the non-titrated rapid 1-hour infusion protocol following tolerance of induction dosing at 0, 2, and 6 weeks. Patients were included from Dec

APA, Harvard, Vancouver, ISO, and other styles

6

Batool, S., M. A. Abdullah, K. Anderson, and S. Bawa. "THU0158 ‘ONE IS NOT ENOUGH’ - RITUXIMAB SINGLE VS DOUBLE INFUSION PROTOCOL IN TREATMENT OF ESTABLISHED RHEUMATOID ARTHRITIS – REAL LIFE EXPERIENCE OF GARTNAVEL GENERAL HOSPITAL, GLASGOW, UK." Annals of the Rheumatic Diseases 79, Suppl 1 (2020): 294.2–294. http://dx.doi.org/10.1136/annrheumdis-2020-eular.4297.

Full text

Abstract:

Background:Rituximab (RTX), chimeric anti-CD20 monoclonal antibody, is recommended as a treatment option for rheumatoid arthritis (RA) patients who had inadequate response or are intolerant to other DMARDs including at least one anti-TNF inhibitor1. The most cost-effective dosing and retreatment schedule remains to be defined. Based on series of case reports and observational studies, it is suggested that retreatment with RTX 1g single infusion provides similar clinical outcomes compared with 2 x 1g infusions2. We report our experience of using single infusion in treatment of established RA.Ob

APA, Harvard, Vancouver, ISO, and other styles

7

Casey, Julia. "Effectiveness of scheduled vital signs assessment during infliximab infusions in detecting infusion reactions: a multi-centre retrospective data review." British Journal of Nursing 31, no. 2 (2022): S16—S22. http://dx.doi.org/10.12968/bjon.2022.31.2.s16.

Full text

Abstract:

Purpose: To determine if scheduled vital signs monitoring is useful in the detection of infusion reactions to infliximab (IFX). Methods: The infusion records of 35,988 IFX infusions completed in 2017 were reviewed for infusion reactions that occurred during the infusion, which were then examined further to determine how those infusion reactions were detected. Results: Of the 90 complete infusion reaction records reviewed, no infusion reactions (0) were detected by scheduled vital signs assessment. Conclusions: According to the infusion reaction data reviewed, scheduled vital sign assessment di

APA, Harvard, Vancouver, ISO, and other styles

8

Yu, Denny, Marian Obuseh, and Poching DeLaurentis. "Quantifying the Impact of Infusion Alerts and Alarms on Nursing Workflows: A Retrospective Analysis." Applied Clinical Informatics 12, no. 03 (2021): 528–38. http://dx.doi.org/10.1055/s-0041-1730031.

Full text

Abstract:

Abstract Background Smart infusion pumps affect workflows as they add alerts and alarms in an information-rich clinical environment where alarm fatigue is already a major concern. An analytic approach is needed to quantify the impact of these alerts and alarms on nursing workflows and patient safety. Objectives To analyze a detailed infusion dataset from a smart infusion pump system and identify contributing factors for infusion programming alerts, operational alarms, and alarm resolution times. Methods We analyzed detailed infusion pump data across four hospitals in a health system for up to

APA, Harvard, Vancouver, ISO, and other styles

9

Loonstra, Floor C., Johannis A. van Rossum, Zoé LE van Kempen, Theo Rispens, Bernard MJ Uitdehaag, and Joep Killestein. "Infusion-related events during natalizumab: No need for post-infusion monitoring." Multiple Sclerosis Journal 26, no. 12 (2019): 1590–93. http://dx.doi.org/10.1177/1352458519860415.

Full text

Abstract:

This retrospective cohort study assessed the timing of infusion-related adverse events (IAEs) during natalizumab (NTZ) administration in well-documented relapsing-remitting multiple sclerosis (RRMS) patients who had received NTZ infusions in our centre between 2006 and 2018. In 225 RRMS patients (14,174 NTZ infusions), 276 IAEs (1.95%) occurred in 60 patients. All documented severe IAE occurred during infusion. Of the 19 moderate adverse events, 17 were during infusion. None of the reactions that occurred after the infusion required intervention. These results suggest that post-infusion monito

APA, Harvard, Vancouver, ISO, and other styles

10

Nguyen, Angela, May O'Donnell, Brett Benfield, Marrea Peters, and Alicia Zagel. "Infusing Safety: Comparing Oncology Infusion Outcomes at Home Infusion Services vs. Hospital-Based Outpatient Infusion Centers." Infusion Journal 3, no. 3 (2024): 23–32. https://doi.org/10.70776/miob6792.

Full text

Abstract:

Background Oncology infusions are a cornerstone of cancer treatment, often administered in hospitalbased outpatient departments (HOPDs) due to the controlled environment they offer. However, with the rise of patient-centered care and cost reduction efforts, home infusion services are an increasingly viable alternative for oncology treatments, though some professional groups have concerns about safety. To address these concerns, this study compares safety outcomes of oncology infusions administered through home infusion (HI) to those administered in HOPDs. Methods This retrospective study analy

APA, Harvard, Vancouver, ISO, and other styles

11

Waterson, James, and Arkadiusz Bedner. "Types and Frequency of Infusion Pump Alarms and Infusion-Interruption to Infusion-Recovery Times for Critical Short Half-Life Infusions: Retrospective Data Analysis." JMIR Human Factors 6, no. 3 (2019): e14123. http://dx.doi.org/10.2196/14123.

Full text

Abstract:

Background Alarm fatigue commonly leads to a reduced response to alarms. Appropriate and timely response to intravenous pump alarms is crucial to infusion continuity. The difficulty of filtering out critical short half-life infusion alarms from nonurgent alarms is a key challenge for risk management for clinicians. Critical care areas provide ample opportunities for intravenous medication error with the frequent administration of high-alert, critical short half-life infusions that require rigorous maintenance for continuity of delivery. Most serious medication errors in critical care occur dur

APA, Harvard, Vancouver, ISO, and other styles

12

Gaffney, Kelly J., Elizabeth M. Dahl, Michael P. Stanton, Elizabeth Starek, and Anthony S. Zembillas. "Rapid-Infusion Rituximab in a Pediatric Population." Journal of Pediatric Pharmacology and Therapeutics 25, no. 3 (2020): 215–19. http://dx.doi.org/10.5863/1551-6776-25.3.215.

Full text

Abstract:

OBJECTIVES The use of rapid rituximab infusion in certain pediatric populations has generally been regarded as safe. The safety of our institution's rapid rituximab protocol was evaluated. METHODS The primary end point was the number of and severity of adverse drug reactions. Secondary end points included a description of the patient population defined by the indication, dose, and number of rituximab infusions administered. Additionally, the difference in infusion times in hours of those receiving rapid rituximab infusions versus the theoretical infusion time of subsequent administration rate

APA, Harvard, Vancouver, ISO, and other styles

13

von Roemeling, R., and W. J. Hrushesky. "Circadian patterning of continuous floxuridine infusion reduces toxicity and allows higher dose intensity in patients with widespread cancer." Journal of Clinical Oncology 7, no. 11 (1989): 1710–19. http://dx.doi.org/10.1200/jco.1989.7.11.1710.

Full text

Abstract:

Continuous long-term 5-fluoro-2'-deoxyuridine (floxuridine; FUDR) infusion frequently causes severe and dose-limiting gastrointestinal toxicity when administered at a constant rate at commonly prescribed dose levels. In preclinical studies, a circadian infusion pattern peaking late in the daily activity phase was better tolerated and had superior antitumor activity than a constant infusion against a transplanted tumor. Based upon these data and upon other chronobiological cytokinetic and pharmacologic considerations, we compared a circadian patterned variable rate infusion with a maximal flow

APA, Harvard, Vancouver, ISO, and other styles

14

Bloomquist, Alison, and Laura Seiberlich. "Reducing Intermittent Infusion Syringe Pump Errors via Weight-Based Safety Parameters." Biomedical Instrumentation & Technology 49, s4 (2015): 31–36. http://dx.doi.org/10.2345/0899-8205-49.s4.31.

Full text

Abstract:

Historically, smart infusion pumps with dose error reduction software were implemented to improve safety associated with programming of continuous infusion modes on large-volume infusion pumps. Much of the published literature related to smart infusion pumps and safety alerts is focused on continuous medication infusions, with little available information related to their use with intermittent infusions. As a result of the focus on continuous infusions, an impression exists that intermittent infusions are less prone to programming errors and/or do not require comparably rigorous safety paramet

APA, Harvard, Vancouver, ISO, and other styles

15

Alrifai, Nada, Zara Alvi, Patricia Bononi, et al. "ODP231 Outcomes of Weight-based vs. Constant-based Insulin Infusion for Treatment of Diabetic Ketoacidosis in Non-ICU Patients." Journal of the Endocrine Society 6, Supplement_1 (2022): A328—A329. http://dx.doi.org/10.1210/jendso/bvac150.681.

Full text

Abstract:

Abstract Background The American Diabetes Association's guidelines for treatment of diabetic ketoacidosis (DKA) have explicit guidelines on the use of a weight-based insulin infusion to rapidly correct a patient's blood glucose and acidosis. Despite close monitoring, insulin infusion requires close monitoring and carries a risk of hypoglycemia, leading to adverse outcomes. While weight-based insulin infusions are designed to infuse a steady rate of insulin based on the patient's weight, constant-based insulin infusions are designed to infuse insulin based on a "constant" which represents the p

APA, Harvard, Vancouver, ISO, and other styles

16

Hart, J. W., J. R. Murillo, M. S. Oholendt, and H. A. Preti. "Assessment of safety with abbreviated, weight-based bevacizumab infusions in a variety of solid tumors." Journal of Clinical Oncology 25, no. 18_suppl (2007): 19674. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.19674.

Full text

Abstract:

19674 Background: Bevacizumab (BEV), a humanized monoclonal antibody that neutralizes vascular endothelial growth factor, has shown improved responses in patients with colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) while displaying activity in a variety of other solid tumors. Phase I clinical trials with BEV utilized standard 90- 60-, and 30-minute infusions for 1st, 2nd, and subsequent infusions, as tolerated; initial doses reported less than 3% incidence of infusion-related adverse events (AEs), with 0.2% grade III/IV reactions. Recommended infusion rates for BEV remain uncha

APA, Harvard, Vancouver, ISO, and other styles

17

Aurran-Schleinitz, Thérèse, Gwaenaelle Gravis, Martine Vittot, et al. "“One Hour” Rituximab Infusion Is Safe and Improves Patient Care and Outpatient Unit Management." Blood 106, no. 11 (2005): 4759. http://dx.doi.org/10.1182/blood.v106.11.4759.4759.

Full text

Abstract:

Abstract Background: Administration of the monoclonal anti-CD20 antibody Rituximab has been associated with infusional toxicity, leading to strict guidelines of use, i.e., infusion times from 4 to 6 hours. Even with pretreatment acetaminophen and diphenydramine, grade 3/4 adverse events including bronchospasm and hypotension occur in ~10% of patients with the first, and in < 2% with subsequent infusions. Presence of circulating malignant CD20 bearing cells represents a risk factor for developing grade 3/4 reactions. The pathophysiogy of this infusional toxicity is thought to be a “cytokine

APA, Harvard, Vancouver, ISO, and other styles

18

Hales, Jena B., Amber C. Ocampo, Nicola J. Broadbent, and Robert E. Clark. "Hippocampal Infusion of Zeta Inhibitory Peptide Impairs Recent, but Not Remote, Recognition Memory in Rats." Neural Plasticity 2015 (2015): 1–7. http://dx.doi.org/10.1155/2015/847136.

Full text

Abstract:

Spatial memory in rodents can be erased following the infusion of zeta inhibitory peptide (ZIP) into the dorsal hippocampus via indwelling guide cannulas. It is believed that ZIP impairs spatial memory by reversing established late-phase long-term potentiation (LTP). However, it is unclear whether other forms of hippocampus-dependent memory, such as recognition memory, are also supported by hippocampal LTP. In the current study, we tested recognition memory in rats following hippocampal ZIP infusion. In order to combat the limited targeting of infusions via cannula, we implemented a stereotaxi

APA, Harvard, Vancouver, ISO, and other styles

19

Nduom, Edjah K., Stuart Walbridge, and Russell R. Lonser. "Comparison of pulsed versus continuous convective flow for central nervous system tissue perfusion." Journal of Neurosurgery 117, no. 6 (2012): 1150–54. http://dx.doi.org/10.3171/2012.9.jns12506.

Full text

Abstract:

Object Although pulsatile and continuous infusion paradigms have been described for convective delivery of drugs, the effectiveness and properties of each flow paradigm are unknown. To determine the effectiveness and properties of pulsatile and continuous convective infusion paradigms, the authors compared these convective flow methods in the gray and white matter of primates. Methods Six primates (Macaca mulatta) underwent convective infusion of Gd-DPTA (5 mM) into the cerebral gray matter (thalamus) or white matter (frontal lobe) using pulsed (intermittent pulses of 15 μl/min) or continuous

APA, Harvard, Vancouver, ISO, and other styles

20

Avery, Pearl, Lisa Younge, Anya St Clair-Jones, et al. "Limiting infusion and observation times for infliximab and vedolizumab in the COVID-19 pandemic: a UK multicentre audit of practice and safety." Gastrointestinal Nursing 18, no. 8 (2020): 30–36. http://dx.doi.org/10.12968/gasn.2020.18.8.30.

Full text

Abstract:

Background: Infusions units in the UK are under increasing pressure, and this has been increased by the SARS-COV-2 pandemic. People with inflammatory bowel disease (IBD) are considered vulnerable, requiring enhanced social distancing or shielding, as defined in the UKz government's recommendations for COVID-19. Evidence that post-infusion observation time is unnecessary for infliximab (IFX) and vedolizumab (VDZ) exists in the literature, but the summary of product characteristics for both agents states that anywhere from 0.5 hours to 2 hours of observation post-infusion is required. Methods: A

APA, Harvard, Vancouver, ISO, and other styles

21

Sapsford, D. J., and C. Howard. "Epidural infusions-shortage of infusion devices." Anaesthesia 43, no. 4 (2007): 332. http://dx.doi.org/10.1111/j.1365-2044.1988.tb08991.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Shrestha, Sofia, Dana Simonson, and Alicia Zagel. "A Pilot Study of Ocrelizumab Infusion Reaction Rates Among Multiple Sclerosis Patients Treated in a Hospital and 2 Outpatient Sites of Care." Infusion Journal 1, no. 3 (2022): 10–17. https://doi.org/10.70776/knob7854.

Full text

Abstract:

Objectives: Economic data on site of care optimization is well-established, yet limited data exist on the safety of administering ocrelizumab in home infusion settings. Ocrelizumab is administered for the treatment of multiple sclerosis and carries a warning for the risk of infusion-related reactions (IRRs) during administration. The study objective was to measure the incidence and severity of infusion-related reactions in patients receiving ocrelizumab administered in both hospital-based and outpatient sites of care. Methods: This was a retrospective study of patients who received ocrelizumab

APA, Harvard, Vancouver, ISO, and other styles

23

POHL, Nyssa, and Russell DALTON. "The Effectiveness of Intra-Uterine Platelet Rich Plasma Infusion for Improving Endometrial Thickness and Pregnancy Outcomes: A Pilot Study Analysis." Fertility & Reproduction 04, no. 03n04 (2022): 206. http://dx.doi.org/10.1142/s2661318222741170.

Full text

Abstract:

Background: Platelet rich plasma (PRP) is well researched and utilized in many medical fields to increase angiogenesis, tissue healing and regeneration a . Recent studies have reported that intra-uterine PRP infusions when used during frozen embryo transfer (FET) cycles, can similarly affect endometrial proliferation, resulting in decreased cycle cancellation rates and improved endometrial thickness and pregnancy outcomes in women with thin linings b , c Aim: To establish if intra-uterine PRP infusions can increase endometrial thickness and improve pregnancy rates in women with a history of th

APA, Harvard, Vancouver, ISO, and other styles

24

Gill, David Michael, Wendy Burr, Mckenzie Bell, et al. "Barriers to patient-centered oncology care: Pilot study of home infusion of anticancer immunotherapy." Journal of Clinical Oncology 39, no. 28_suppl (2021): 36. http://dx.doi.org/10.1200/jco.2020.39.28_suppl.36.

Full text

Abstract:

36 Background: ASCO published a position statement regarding home infusion of anticancer therapy in June 2020. This statement recommends independent research to evaluate the safety and effectiveness of home infusions. Intermountain Healthcare (IM) incorporated this statement into its oncology care with an IRB-approved, prospective single-arm pilot study to determine the safety and feasibility of home administration of checkpoint inhibitor (CPI) immunotherapy with synchronous telemedicine visits. Methods: Patients with cancer receiving treatment at Intermountain Medical Center and Intermountain

APA, Harvard, Vancouver, ISO, and other styles

25

Tung, Tsan-Hua, Poching DeLaurentis, and Yuehwern Yih. "Uncovering Discrepancies in IV Vancomycin Infusion Records between Pump Logs and EHR Documentation." Applied Clinical Informatics 13, no. 04 (2022): 891–900. http://dx.doi.org/10.1055/s-0042-1756428.

Full text

Abstract:

Abstract Background Infusion start time, completion time, and interruptions are the key data points needed in both area under the concentration–time curve (AUC)- and trough-based vancomycin therapeutic drug monitoring (TDM). However, little is known about the accuracy of documented times of drug infusions compared with automated recorded events in the infusion pump system. A traditional approach of direct observations of infusion practice is resource intensive and impractical to scale. We need a new methodology to leverage the infusion pump event logs to understand the prevalence of timestamp

APA, Harvard, Vancouver, ISO, and other styles

26

Błaszczyk, Alfred, Sylwia Sady, Zuzanna Płaczek, et al. "Health-promoting Properties Infusions of Hibiscus Flowers and Selected Berry Fruit Processing By-products." Engineering Sciences And Technologies 2023, no. 39 (2023): 65–74. http://dx.doi.org/10.15611/nit.2023.39.05.

Full text

Abstract:

Aim: This study aimed to compare the health-promoting properties of hibiscus flowers infusions with pomace infusions from black chokeberry, blackcurrant, raspberry and strawberry. Methodology: Five types of fruit pomace infusions were selected as the research material: hibiscus flowers infusion and infusions from black chokeberry, blackcurrant, raspberry and strawberry pomace. The total polyphenol content, antioxidant activity and colour parameters were determined. Results: The highest content of phenolic compounds was found in hibiscus flowers infusion (453.25 mg GAE/L of infusion). Hibiscus

APA, Harvard, Vancouver, ISO, and other styles

27

Nguyen, My L., Catherine Burdalski, Syed Abbas Ali, Lindsay Kohler, and Steven Gilmore. "Prevention and Management of Daratumumab Mediated Infusion Related Hypersensitivity Reactions Pre-and Post-Implementation of Rapid Infusion Protocol." Blood 134, Supplement_1 (2019): 5811. http://dx.doi.org/10.1182/blood-2019-125391.

Full text

Abstract:

Background: Multiple Myeloma (MM) is defined as a clonal proliferation of malignant bone marrow plasma cells with high and uniform expression of CD 38 (Kumar et al, J Natl Compr Canc Netw. 2019; 3 and Lin et al, Am J Clin Pathol. 2004; 121:482-488). Daratumumab, a human IgGk monoclonal antibody, targets and binds to CD38, induces antibody dependent cell mediated cytotoxicity, complement activation, and antibody mediated phagocytosis (Prescribing information. Daratumumab; Janssen Biotech, Inc 2016). Daratumumab is associated with infusion related reactions (IRRs), which present with symptoms of

APA, Harvard, Vancouver, ISO, and other styles

28

Salar, Antonio, Dolors Casao, Carmen Pedro, et al. "Rapid Infusion of Rituximab with or without Steroid Containing Chemotherapy. A Single Centre Experience." Blood 106, no. 11 (2005): 4772. http://dx.doi.org/10.1182/blood.v106.11.4772.4772.

Full text

Abstract:

Abstract Introduction: Infusion-related toxicity is frequent after the administration of Rituximab despite the fact that strict guidelines have been recommended. Recently, a rapid rituximab infusion schedule in combination with a steroid containing chemotherapy regimen was well tolerated and safe. Purpose: To investigate the feasibility of a rapid infusion of rituximab with or without steroid containing chemotherapy. Methods: Inclusion criteria: lymphoproliferative disorder CD20+ and having been treated with a first infusion of rituximab according to the product monograph. Exclusion criteria:

APA, Harvard, Vancouver, ISO, and other styles

29

Jiang, Joshua, Erica S. Martinez, Gary J. Schiller, Mary E. Sehl, and Amie S. Patel. "Effect of Crizanlizumab Infusion during Vaso-Occlusive Crises on Acute Care Utilization for Pain Control." Blood 144, Supplement 1 (2024): 5309. https://doi.org/10.1182/blood-2024-202859.

Full text

Abstract:

Introduction Crizanlizumab is a humanized monoclonal antibody which blocks P-selectin, a cellular adhesion molecule expressed on activated endothelium and involved in recruiting leukocytes to sites of inflammation. In patients with sickle cell disease, P-selectin mediates the adhesion of sickle erythrocytes to the endothelium, leading to vessel occlusion, tissue ischemia, and pain. P-selectin is also expressed on activated platelets, which form aggregates with neutrophils that further perturb normal blood flow in sickle cell disease. The phase 2 SUSTAIN trial presented evidence that crizanlizu

APA, Harvard, Vancouver, ISO, and other styles

30

Hartung, Hans-Peter. "Ocrelizumab shorter infusion." Neurology - Neuroimmunology Neuroinflammation 7, no. 5 (2020): e807. http://dx.doi.org/10.1212/nxi.0000000000000807.

Full text

Abstract:

ObjectiveTo assess the safety of ocrelizumab (OCR) shorter duration infusion in patients with MS.MethodsENSEMBLE PLUS is a randomized, double-blind substudy to the single-arm ENSEMBLE study (NCT03085810). In ENSEMBLE, patients with early stage relapsing-remitting MS received OCR 600 mg initially as two 300 mg IV infusions 2 weeks apart and subsequently as a single 3.5-hour 600 mg infusion every 24 weeks for 192 weeks. In ENSEMBLE PLUS, OCR 600 mg administered over the approved 3.5-hour infusion time (conventional duration) is compared with a 2-hour infusion (shorter duration). The primary end

APA, Harvard, Vancouver, ISO, and other styles

31

Jacob, Brigid, Maria Jamil, Shahm Raslan, et al. "Infusion Reactions with Alternative Therapies during the National Shortage of Iron Dextran." Blood 142, Supplement 1 (2023): 7338. http://dx.doi.org/10.1182/blood-2023-178234.

Full text

Abstract:

Introduction The national shortage of intravenous iron dextran has required patients to receive more alternative iron infusions, such as iron sucrose and sodium ferric gluconate/sucrose, since January 2023. While prior studies have evaluated rates of infusion reactions among some commonly used intravenous iron formulations, data is lacking among differing doses of iron formulations and especially in the setting of this iron dextran shortage. Clinicians at our institution generally observed more adverse reactions with alternative iron infusions during the national shortage of iron dextran compa

APA, Harvard, Vancouver, ISO, and other styles

32

Patel, Jolly R., Viet Q. Ho, Melissa L. Teichman, et al. "Rapid Infusion Rituximab in Maintenance Therapy: Is It Feasible?" Blood 118, no. 21 (2011): 4973. http://dx.doi.org/10.1182/blood.v118.21.4973.4973.

Full text

Abstract:

Abstract Abstract 4973 Background/Rationale: Rituximab is an anti-CD-20 monoclonal antibody used in the management of lymphoproliferative disorders. Rituximab is indicated in maintenance therapy for follicular cell lymphoma and can be administered once every 2 months, once every 3 months, or weekly for 4 weeks every 6 months. The use of maintenance rituximab has improved progression free survival and overall survival in low grade follicular lymphomas. Although rapid rituximab infusions have been studied extensively, there is little data on the use of rapid infusions during maintenance therapy

APA, Harvard, Vancouver, ISO, and other styles

33

Broderick, Tom L., Paul Poirier, Angelo Tremblay, Claude Catellier, and André Nadeau. "Effect of exogenous insulin on plasma free carnitine levels during exercise in normal man." Canadian Journal of Physiology and Pharmacology 67, no. 12 (1989): 1598–601. http://dx.doi.org/10.1139/y89-257.

Full text

Abstract:

Preliminary data from our laboratory have shown that the decrease in plasma free carnitine levels normally found during prolonged exercise is blunted in type 1 diabetic man. This study was designed to test the hypothesis that this might be due to the sustained peripheral hyperinsulinemia seen during exercise in diabetics treated by subcutaneous insulin. Ten male subjects underwent 90 min of cycle ergometry at 60% of their maximal oxygen uptake capacity on two occasions, one with and the other without a constant 0.13 mU∙kg−1∙min−1 i.v. insulin infusion. Blood samples were taken at rest, during

APA, Harvard, Vancouver, ISO, and other styles

34

Schoorlemmer, G. H. M., A. K. Johnson, and R. L. Thunhorst. "Effect of hyperosmotic solutions on salt excretion and thirst in rats." American Journal of Physiology-Regulatory, Integrative and Comparative Physiology 278, no. 4 (2000): R917—R923. http://dx.doi.org/10.1152/ajpregu.2000.278.4.r917.

Full text

Abstract:

We investigated urinary changes and thirst induced by infusion of hyperosmotic solutions in freely moving rats. Intracarotid infusions of 0.3 M NaCl (4 ml/20 min, split between both internal carotid arteries) caused a larger increase in excretion of Na+ and K+ than intravenous infusions, indicating that cephalic sensors were involved in the response to intracarotid infusions. Intravenous and intracarotid infusions of hyperosmotic glycerol or urea (300 mM in 150 mM NaCl) had little or no effect, suggesting the sensors were outside the blood-brain barrier (BBB). Intracarotid infusion of hyperton

APA, Harvard, Vancouver, ISO, and other styles

35

Goodrich, Drew, Alyssa George, Jennifer Stein, Robert Koziol, and Brienne Costigan. "Retrospective Cohort Analysis of 1-Hour Infliximab Infusions in Pediatric Patients." Journal of Pediatric Pharmacology and Therapeutics 30, no. 1 (2025): 65–69. https://doi.org/10.5863/1551-6776-30.1.65.

Full text

Abstract:

OBJECTIVE This study aimed to characterize and assess the safety of a 1-hour infliximab infusion in a cohort of pediatric patients. METHODS A retrospective chart review of pediatric patients that received a 1-hour infliximab or its biosimilar infusion for a gastrointestinal or rheumatologic condition was conducted. Infusions were included if the patient had at least 3 infusions for rheumatology patients and 4 for gastroenterology patients. Patients who were not transitioned to the rapid, 1-hour infusion were excluded. Baseline characteristics, including age, weight, indication, dose, the use o

APA, Harvard, Vancouver, ISO, and other styles

36

Choquette, Denis, Rafat Faraawi, Andrew Chow, Jude Rodrigues, William J. Bensen, and Francois Nantel. "Incidence and Management of Infusion Reactions to Infliximab in a Prospective Real-world Community Registry." Journal of Rheumatology 42, no. 7 (2015): 1105–11. http://dx.doi.org/10.3899/jrheum.140538.

Full text

Abstract:

Objective.Infliximab (IFX) is a therapeutic monoclonal antibody targeting tumor necrosis factor-α indicated in the treatment of chronic inflammatory diseases. IFX is administered by intravenous infusion and may be associated with different types of infusion reactions.Methods.RemiTRAC Infusion (NCT00723905) is a Canadian observational registry in which patients receiving IFX are followed prospectively to document premedication use, adverse events, infusion reactions, and the management of infusion reactions. The primary endpoint was to assess factors associated with infusion reactions.Results.T

APA, Harvard, Vancouver, ISO, and other styles

37

Lo Turco, Vincenzo, Vincenzo Nava, Angela Giorgia Potortì, Benedetta Sgrò, Maria Aurora Arrigo, and Giuseppa Di Bella. "Total Polyphenol Contents and Mineral Profiles in Commercial Wellness Herbal Infusions: Evaluation of the Differences between Two Preparation Methods." Foods 13, no. 13 (2024): 2145. http://dx.doi.org/10.3390/foods13132145.

Full text

Abstract:

The popularity of the consumption of wellness herbal teas is due to the many health-promoting properties they seem to possess. Modern preparation methods using coffee machines are also popular today. Therefore, the purpose of this research was to evaluate differences in infusions obtained by the traditional method using filters and by espresso coffee machines using pods. In this regard, different herbal materials were selected and purchased in two different types of herbal containers, and the corresponding infusions were analyzed for the contents of total polyphenols and mineral elements. Resu

APA, Harvard, Vancouver, ISO, and other styles

38

KELSALL, JOHN, PAMELA ROGERS, GRISELDA GALINDO, and MARY A. De VERA. "Safety of Infliximab Treatment in Patients with Rheumatoid Arthritis in a Real-world Clinical Setting: Description and Evaluation of Infusion Reactions." Journal of Rheumatology 39, no. 8 (2012): 1539–45. http://dx.doi.org/10.3899/jrheum.110956.

Full text

Abstract:

Objective.To describe acute and delayed infusion reactions in a large cohort of patients with inflammatory arthritis, treated with infliximab (IFX).Methods.We conducted a retrospective chart review of patients treated with IFX at the Mary Pack Arthritis Centre between 2000 and 2008. The primary outcome was the occurrence of acute infusion reactions during infusions or 1–2 hours after each infusion, and secondary outcome was the occurrence of delayed infusion reactions 1–14 days after an infusion. Descriptive analyses were conducted to summarize study outcomes and identify trends over followup.

APA, Harvard, Vancouver, ISO, and other styles

39

Condino, Adria A., Sara Fidanza, and Edward J. Hoffenberg. "A Home Infliximab Infusion Program." Journal of Pediatric Gastroenterology and Nutrition 40, no. 1 (2005): 67–69. http://dx.doi.org/10.1002/j.1536-4801.2005.tb00928.x.

Full text

Abstract:

ABSTRACTIntroduction:Infliximab is a promising advance in the treatment of pediatric inflammatory bowel disease. Infliximab is an effective therapy for selected children with Crohn disease but is both costly and time consuming.Objectives:To analyze our center's experience with a program of home‐based infliximab infusion.Methods:Between September, 2001, and October, 2003 we reviewed the charts of all children receiving home infliximab infusions focusing on cost, safety, and patient satisfaction. Children were enrolled in the home infusion program if they were compliant with hospital‐based infli

APA, Harvard, Vancouver, ISO, and other styles

40

Legeay, Clément, Henrique Bittencourt, Elie Haddad, Laurence Spiesser-Robelet, Valérie Thépot-Seegers, and Roxane Therrien. "A Retrospective Study on Infusion-Related Reactions to Rituximab in a Heterogeneous Pediatric Population." Journal of Pediatric Pharmacology and Therapeutics 22, no. 5 (2017): 369–74. http://dx.doi.org/10.5863/1551-6776-22.5.369.

Full text

Abstract:

OBJECTIVES To assess risks and outcomes of infusion-related reactions to rituximab in a heterogeneous pediatric population. METHODS All patients who received rituximab between July 2010 and July 2012 were retrieved from the pharmacy software and included for analysis. Data were collected according to 4 categories: demographic data, infusion data, infusion-related reactions, and biological data considered as risk factors (i.e., absolute lymphocyte count, lactate dehydrogenase levels). RESULTS Sixty-seven patients treated for a total of 17 different indications were included. A total of 282 ritu

APA, Harvard, Vancouver, ISO, and other styles

41

Hubert, Dominique, Evelyne Le Roux, Thibaud Lavrut, et al. "Continuous versus Intermittent Infusions of Ceftazidime for Treating Exacerbation of Cystic Fibrosis." Antimicrobial Agents and Chemotherapy 53, no. 9 (2009): 3650–56. http://dx.doi.org/10.1128/aac.00174-09.

Full text

Abstract:

ABSTRACT The present multicenter, randomized crossover study compared the safety and efficacy of continuous infusion with those of short infusions of ceftazidime in patients with cystic fibrosis. Patients with chronic Pseudomonas aeruginosa colonization received two successive courses of intravenous tobramycin and ceftazidime (200 mg/kg of body weight/day) for pulmonary exacerbation administered as thrice-daily short infusions or as a continuous infusion. The primary endpoint was the variation in the forced expiratory volume in 1 s (FEV1) during the course of antibiotic treatment. Sixty-nine o

APA, Harvard, Vancouver, ISO, and other styles

42

Yu, Denny, Kang-Yu Hsu, Joon Hong Kim, and Poching DeLaurentis. "Infusion pump informatics approach to quantify impact of alerts and alarms on healthcare delivery." Proceedings of the Human Factors and Ergonomics Society Annual Meeting 61, no. 1 (2017): 681–85. http://dx.doi.org/10.1177/1541931213601657.

Full text

Abstract:

Infusion pumps are medical devices that deliver medication, fluids, and nutrients in a precise and controlled manner that is critical to patient care. This study proposes using infusion pump informatics on all-infusion datasets to understand current impact of alerts and alarms on patient care and health practitioner workflow. All-infusion datasets contain infusion data for both normal and abnormal use, i.e., error states. Ten months of continuous data was collected from one health institution. Analysis of variance with log-transformation and logistic regressions were used to analysis contribut

APA, Harvard, Vancouver, ISO, and other styles

43

Sehn, Laurie H., Jane Donaldson, Allison Filewich, et al. "Rapid Infusion Rituximab in Combination with Steroid Containing Chemotherapy Can Be Given Safely and Substantially Reduces Resource Utilization." Blood 104, no. 11 (2004): 1407. http://dx.doi.org/10.1182/blood.v104.11.1407.1407.

Full text

Abstract:

Abstract Background Administration of rituximab, a chimeric anti-CD20 monoclonal antibody, can be associated with substantial infusion-related toxicity, including hypersensitivity reactions causing fever, rash, cardiovascular and respiratory compromise and rarely a fatal cytokine release syndrome. The risk of grade 3/4 infusion reactions is greatest with the first infusion (7%), and lower for all subsequent infusions (2% for fourth infusion). To minimize the risk of reaction, strict guidelines for administration have been developed, requiring lengthy infusion times (average 5–6 h for first inf

APA, Harvard, Vancouver, ISO, and other styles

44

REES, F., A. Packham, C. Blake, E. Hills, G. Scutt, and A. St Clair-Jones. "P604 Can we reduce intravenous monoclonal antibody observation times without compromising patient safety? A single centre retrospective observational study." Journal of Crohn's and Colitis 14, Supplement_1 (2020): S504—S505. http://dx.doi.org/10.1093/ecco-jcc/jjz203.732.

Full text

Abstract:

Abstract Background Monoclonal antibodies (MAbs) are integral to inflammatory bowel disease (IBD) management. The administration of intravenous (IV) MAbs, infliximab and vedolizumab, for Brighton and Sussex University Hospital patients is via an outpatient clinic. Licensing specifies lengthy observation times; infliximab for induction (infusion 1 to 3) and maintenance (infusion 4 onwards) requires 1 to 2 h observation. Vedolizumab for induction (infusion 1 to 2) requires 2 h observation and maintenance (infusion 3 onwards) 1-h observation. This can affect waiting times; 33% UK patients waited

APA, Harvard, Vancouver, ISO, and other styles

45

Fellows, I. W., T. Bennett, and I. A. Macdonald. "The effect of Adrenaline upon Cardiovascular and Metabolic Functions in Man." Clinical Science 69, no. 2 (1985): 215–22. http://dx.doi.org/10.1042/cs0690215.

Full text

Abstract:

1. On three separate occasions, at least 1 week apart, seven young healthy male subjects received intravenous infusions of either adrenaline, 50 ng min−1 kg−1 (high A), adrenaline, 10 ng min−1 kg−1 (low A) or sodium chloride solution (saline :154 mmol of NaCl/1) plus ascorbic acid, 1 mg/ml (control), over 30 min. 2. Venous adrenaline concentrations of 2.19 ± 0.15 nmol/l, 0.73 ± 0.08 nmol/l and 0.15 ± 0.03 nmol/l were achieved during the high A, low A and control infusions respectively. 3. Heart rate rose significantly by 19 ± 3 beats/min (high A) and by 6 ± 1 beats/min (low A). Heart rate rema

APA, Harvard, Vancouver, ISO, and other styles

46

Musa, Rohae, Maria Giannakos, and Suzanne Kluge. "The Safety of Natalizumab Administration in the Home During the COVID-19 Pandemic for Patients with Multiple Sclerosis." Infusion Journal 2, no. 1 (2023): 1–3. https://doi.org/10.70776/exvm6354.

Full text

Abstract:

Background: Multiple sclerosis (MS) is a progressive autoimmune inflammatory disorder causing demyelination and degeneration of the central nervous system. Natalizumab is a highly effective monoclonal antibody for the treatment of relapsing-remitting multiple sclerosis (RRMS).1 It is usually delivered as 300 mg 1-hour intravenous infusion every 4 weeks.1 Natalizumab is generally well tolerated, however, there are infusion-related reactions associated with the drug, and a risk of progressive multifocal leukoencephalopathy (PML.) Patients were previously required to receive the infusions in an a

APA, Harvard, Vancouver, ISO, and other styles

47

Rashid, Iqbal, and Mustafa Bseikri. "0780 Iron Sucrose Infusions for Pediatric Sleep Related Movement Disorders." SLEEP 46, Supplement_1 (2023): A344. http://dx.doi.org/10.1093/sleep/zsad077.0780.

Full text

Abstract:

Abstract Introduction Sleep related movement disorders (SRMD) such as restless leg syndrome (RLS), periodic limb movement disorder (PLMD), and restless sleep disorder (RSD) are common diagnoses among children referred to pediatric sleep clinics, particularly among children with neurodevelopmental disorders such as ASD. These disorders have been associated with low iron status, and evidence demonstrates clinical response to iron supplementation. Oral iron supplementation is often used as a first step in management, although some children do not manifest an adequate response in serum ferritin le

APA, Harvard, Vancouver, ISO, and other styles

48

Ho, M., J. Armstrong, D. McMahon, et al. "A phase 1 study of adoptive transfer of autologous CD8+ T lymphocytes in patients with acquired immunodeficiency syndrome (AIDS)-related complex or AIDS." Blood 81, no. 8 (1993): 2093–101. http://dx.doi.org/10.1182/blood.v81.8.2093.2093.

Full text

Abstract:

Abstract Based on preclinical studies showing that CD8+ T lymphocytes of human immunodeficiency syndrome (HIV)-infected subjects have anti-HIV activities, a phase 1 study was undertaken to determine the safety and feasibility of infusing in vitro purified, activated, and expanded CD8+ cells as a therapeutic measure in seven patients with acquired immunodeficiency syndrome (AIDS)-related complex (ARC) or AIDS. Autologous CD8+ cells were first selectively isolated in monoclonal antibody-coated flasks from peripheral blood mononuclear cells recovered by leukapheresis. They were then cultured and

APA, Harvard, Vancouver, ISO, and other styles

49

Ho, M., J. Armstrong, D. McMahon, et al. "A phase 1 study of adoptive transfer of autologous CD8+ T lymphocytes in patients with acquired immunodeficiency syndrome (AIDS)-related complex or AIDS." Blood 81, no. 8 (1993): 2093–101. http://dx.doi.org/10.1182/blood.v81.8.2093.bloodjournal8182093.

Full text

Abstract:

Based on preclinical studies showing that CD8+ T lymphocytes of human immunodeficiency syndrome (HIV)-infected subjects have anti-HIV activities, a phase 1 study was undertaken to determine the safety and feasibility of infusing in vitro purified, activated, and expanded CD8+ cells as a therapeutic measure in seven patients with acquired immunodeficiency syndrome (AIDS)-related complex (ARC) or AIDS. Autologous CD8+ cells were first selectively isolated in monoclonal antibody-coated flasks from peripheral blood mononuclear cells recovered by leukapheresis. They were then cultured and expanded

APA, Harvard, Vancouver, ISO, and other styles

50

Harvey, V. J., M. L. Slevin, G. W. Aherne, P. Littleton, A. Johnston, and P. F. Wrigley. "Subcutaneous infusion of bleomycin--a practical alternative to intravenous infusion." Journal of Clinical Oncology 5, no. 4 (1987): 648–50. http://dx.doi.org/10.1200/jco.1987.5.4.648.

Full text

Abstract:

The phase specificity and short half-life of bleomycin make it likely that it would be more effective when administered by continuous infusion. This is supported by studies using cell lines, as well as by animal studies and clinical experience in humans. This study was conducted to compare the pharmacokinetics of intravenous (IV) and subcutaneous infusions of bleomycin. The serum concentrations of bleomycin were measured using a sensitive and specific radioimmunoassay. The results demonstrate similar plasma concentrations and area under the curve for both routes. The subcutaneous infusions wer

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!